Overview

Phase Ⅲ Trial of WBRT Versus Erlotinib Concurrent Whole-brain Radiation Therapy as ﬁrst-line Treatment for Patients With Multiple Brain Metastases From Non-small-cell Lung Cancer(ENTER): a Multicentre, Open-label, Randomised Study

Status:
Completed

Trial end date:
2016-08-01

Target enrollment:

Participant gender:

Summary

1. Verify the effect of Erlotinib concurrent whole-brain radiation therapy as ﬁrst-line treatment for patients with multiple brain metastases from non-small-cell lung cancer to compare with WBRT alone. 2. Verify pre-built EGFR mutation prediction model for NSCLC brain metastases

Phase:

Phase 3

Details

Lead Sponsor:

Daping Hospital and the Research Institute of Surgery of the Third Military Medical University

Treatments:

Erlotinib Hydrochloride